Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Express Scripts
McKesson
Moodys
US Department of Justice
Farmers Insurance
McKinsey
Citi

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 016852

« Back to Dashboard

NDA 016852 describes NORLESTRIN 21 2.5/50, which is a drug marketed by Parke Davis and is included in one NDA. Additional details are available on the NORLESTRIN 21 2.5/50 profile page.

The generic ingredient in NORLESTRIN 21 2.5/50 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for 016852
Tradename:NORLESTRIN 21 2.5/50
Applicant:Parke Davis
Ingredient:ethinyl estradiol; norethindrone acetate
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORAL-21Strength0.05MG;2.5MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fish and Richardson
Healthtrust
McKesson
Dow
US Army
AstraZeneca
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.